Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 2 (2005), Issue 6 (June)

1. Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas.
   J Orthop Sci, 10(3): 258-63. [Abstract] [Full-text]
2. Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study.
   Br J Cancer, 92(11): 1989-96. [Abstract] [Full-text]
3. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.
   Br J Cancer, 92(11): 1976-83. [Abstract] [Full-text]
4. The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration.
   Mutat Res, 583(2): 105-19. [Abstract] [Full-text]
5. Use of hormone replacement therapy (HRT) and survival following breast cancer diagnosis.
   Breast, 14(3): 192-200. [Abstract] [Full-text]
6. Protracted bleeding after hirudin anticoagulation for cardiac surgery in a patient with HIT II and chronic renal failure.
   Artif Organs, 29(6): 507-10. [Abstract] [Full-text]
7. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk.
   Br J Cancer, 92(11): 2049-58. [Abstract] [Full-text]
8. Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients.
   Br J Cancer, 92(11): 1997-2003. [Abstract] [Full-text]
9. Enhanced photodynamic destruction of a transplantable fibrosarcoma using photochemical internalisation of gelonin.
   Br J Cancer, 92(11): 2004-9. [Abstract] [Full-text]
10. Electrokinetic properties of noncharged lipid nanocapsules: influence of the dipolar distribution at the interface.
    Electrophoresis, 26(11): 2066-75. [Abstract] [Full-text]
11. Intensive therapy before or during the conditioning regimen of allogeneic marrow transplantation in adult acute lymphoblastic leukemia patients: we must choose to reduce Toxicity--a Groupe Ouest-Est d'Etude des Leucemies et Autres Maladies du Sang study.
    Biol Blood Marrow Transplant, 11(6): 448-54. [Abstract] [Full-text]
12. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
    Clin Cancer Res, 11(11): 4241-50. [Abstract] [Full-text]
13. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors.
    Clin Cancer Res, 11(11): 4217-24. [Abstract] [Full-text]
14. A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.
    Clin Cancer Res, 11(11): 4144-50. [Abstract] [Full-text]
15. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Cancer Res, 65(11): 4799-808. [Abstract] [Full-text]
16. Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders.
    J Endocrinol, 185(3): 363-72. [Abstract] [Full-text]
17. Gene therapy of pituitary diseases.
    J Endocrinol, 185(3): 353-62. [Abstract] [Full-text]
18. Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients-a pilot uncontrolled study.
    Am J Gastroenterol, 100(6): 1370-5. [Abstract] [Full-text]
19. Detection of a new 3-base pair insertion mutation in the protease gene of human immunodeficiency virus type 1 during highly active antiretroviral therapy (HAART).
    AIDS Res Hum Retroviruses, 21(5): 420-3. [Abstract] [Full-text]
20. Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children.
    AIDS Res Hum Retroviruses, 21(5): 398-406. [Abstract] [Full-text]
21. Components of an integrated microfluidic device for continuous glucose monitoring with responsive insulin delivery.
    Diabetes Technol Ther, 7(3): 536-45. [Abstract] [Full-text]
22. Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect.
    Thyroid, 15(5): 455-60. [Abstract] [Full-text]
23. Photodynamic therapy with verteporfin for choroidal neovascularisations in clinical routine outside the TAP study. One- and two-year results including juxtafoveal and extrafoveal CNV.
    Graefes Arch Clin Exp Ophthalmol, 243(5): 438-45. [Abstract] [Full-text]
24. WST11, a novel water-soluble bacteriochlorophyll derivative; cellular uptake, pharmacokinetics, biodistribution and vascular-targeted photodynamic activity using melanoma tumors as a model.
    Photochem Photobiol, 81(2): 342-51. [Abstract] [Full-text]
25. Photodynamic characterization and in vitro application of methylene blue-containing nanoparticle platforms.
    Photochem Photobiol, 81(2): 242-9. [Abstract] [Full-text]
26. Alterations in mitochondrial and apoptosis-regulating gene expression in photodynamic therapy-resistant variants of HT29 colon carcinoma cells.
    Photochem Photobiol, 81(2): 306-13. [Abstract] [Full-text]
27. Risk Perception and sexual risk behaviors among HIV-positive men on antiretroviral therapy.
    AIDS Behav, 9(2): 167-76. [Abstract] [Full-text]
28. Convection enhanced delivery for the treatment of malignant gliomas: symposium review.
    J Neurooncol, 73(1): 57-69. [Abstract] [Full-text]
29. Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Onkologie, 28(6): 339-44. [Abstract] [Full-text]
30. Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer.
    Onkologie, 28(6): 318-22. [Abstract] [Full-text]
31. Ocular association of HIV infection in the era of highly active antiretroviral therapy and the global perspective.
    Clin Experiment Ophthalmol, 33(3): 317-29. [Abstract] [Full-text]
32. Relationship between histopathological features of chemotherapy treated retinoblastoma and P-glycoprotein expression.
    Clin Experiment Ophthalmol, 33(3): 279-84. [Abstract] [Full-text]
33. Protein-calcium carbonate coprecipitation: a tool for protein encapsulation.
    Biotechnol Prog, 21(3): 918-25. [Abstract] [Full-text]
34. A stopped-flow kinetic study of the assembly of nonviral gene delivery complexes.
    Biophys J, 88(6): 4146-58. [Abstract] [Full-text]
35. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
    Blood, 105(12): 4573-5. [Abstract] [Full-text]
36. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
    Blood, 105(12): 4759-66. [Abstract] [Full-text]
37. Preparation of celecoxib-dimethyl-beta-cyclodextrin inclusion complex: characterization and in vitro permeation study.
    Eur J Med Chem, 40(7): 624-31. [Abstract] [Full-text]
38. Commensal bacteria as a novel delivery system for subunit vaccines directed against agents of bioterrorism.
    Adv Drug Deliv Rev, 57(9): 1392-402. [Abstract] [Full-text]
39. DNA vaccines for biodefence.
    Adv Drug Deliv Rev, 57(9): 1343-61. [Abstract] [Full-text]
40. The role of particle-mediated DNA vaccines in biodefense preparedness.
    Adv Drug Deliv Rev, 57(9): 1315-42. [Abstract] [Full-text]
41. Particulate delivery systems for biodefense subunit vaccines.
    Adv Drug Deliv Rev, 57(9): 1247-65. [Abstract] [Full-text]
42. Medications and their effects on sleep.
    Prim Care, 32(2): 491-509. [Abstract] [Full-text]
43. Evaluation of nationally mandated drug use reviews to improve patient safety in nursing homes: a natural experiment.
    J Am Geriatr Soc, 53(6): 991-6. [Abstract] [Full-text]
44. Medication safety in older adults: home-based practice patterns.
    J Am Geriatr Soc, 53(6): 976-82. [Abstract] [Full-text]
45. Dependence of transgene expression and the relative buffering capacity of dextran-grafted polyethylenimine.
    Mol Pharm, 2(3): 224-32. [Abstract] [Full-text]
46. Iron oxide nanoparticles for sustained delivery of anticancer agents.
    Mol Pharm, 2(3): 194-205. [Abstract] [Full-text]
47. Variant lymphoproliferative disorder of granular lymphocytes (LDGL) following Hodgkin lymphoma.
    Am J Hematol, 79(2): 128-31. [Abstract] [Full-text]
48. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
    Am J Hematol, 79(2): 136-41. [Abstract] [Full-text]
49. Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia.
    Am J Hematol, 79(2): 119-27. [Abstract] [Full-text]
50. Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome.
    Growth Horm IGF Res, 15(3): 231-7. [Abstract] [Full-text]
51. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma.
    Ophthalmology, 112(6): 1151-8. [Abstract] [Full-text]
52. Bacterial ghosts as antigen delivery vehicles.
    Adv Drug Deliv Rev, 57(9): 1381-91. [Abstract] [Full-text]
53. Highly active antiretroviral therapy and human immunodeficiency virus encephalitis.
    Ann Neurol, 57(6): 795-803. [Abstract] [Full-text]
54. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
    Cancer Chemother Pharmacol, 56(2): 182-8. [Abstract] [Full-text]
55. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer.
    Cancer Chemother Pharmacol, 56(2): 199-204. [Abstract] [Full-text]
56. A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer.
    Cancer Chemother Pharmacol, 56(2): 138-44. [Abstract] [Full-text]
57. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
    Cancer Chemother Pharmacol, 56(2): 154-60. [Abstract] [Full-text]
58. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.
    Prostate, 63(4): 385-94. [Abstract] [Full-text]
59. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
    Infection, 33(3): 140-7. [Abstract] [Full-text]
60. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation.
    Eur J Pharm Biopharm, 60(2): 227-40. [Abstract] [Full-text]
61. Cell culture models of the ocular barriers.
    Eur J Pharm Biopharm, 60(2): 207-25. [Abstract] [Full-text]
62. Human respiratory epithelial cell culture for drug delivery applications.
    Eur J Pharm Biopharm, 60(2): 193-205. [Abstract] [Full-text]
63. Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery.
    Eur J Pharm Biopharm, 60(2): 179-91. [Abstract] [Full-text]
64. Hormone replacement therapy and risk of nonfatal acute myocardial infarction in Italy.
    J Clin Epidemiol, 58(7): 747-50. [Abstract] [Full-text]
65. Neoadjuvant and adjuvant therapy for extremity soft tissue sarcomas.
    Hematol Oncol Clin North Am, 19(3): 489-500, vi. [Abstract] [Full-text]
66. Regional variation in medication following coronary events in Germany.
    Int J Cardiol, 102(1): 47-53. [Abstract] [Full-text]
67. An interdisciplinary approach to treating prostate cancer.
    Urology, 65(6): 13-8. [Abstract] [Full-text]
68. Future directions in the treatment of androgen-independent prostate cancer.
    Urology, 65(6): 8-12. [Abstract] [Full-text]
69. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors.
    Nat Biotechnol, 23(6): 709-17. [Abstract] [Full-text]
70. Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study.
    Eur J Cancer, 41(9): 1254-60. [Abstract] [Full-text]
71. Delivery aspects of small peptides and substrates for peptide transporters.
    Eur J Pharm Biopharm, 60(2): 241-5. [Abstract] [Full-text]
72. Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin.
    Nat Biotechnol, 23(6): 725-30. [Abstract] [Full-text]
73. Effect of Hypericum perforatum CO2 extract on the motivational properties of ethanol in alcohol-preferring rats.
    Alcohol Alcohol, 40(4): 291-6. [Abstract] [Full-text]
74. Survival of adults treated for medulloblastoma using paediatric protocols.
    Eur J Cancer, 41(9): 1304-10. [Abstract] [Full-text]
75. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
    Ann Hematol, 84(7): 447-55. [Abstract] [Full-text]
76. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men.
    Eur J Endocrinol, 152(6): 881-6. [Abstract] [Full-text]
77. Effects of weekly paclitaxel or paclitaxel plus carboplatin on functionality and symptoms of geriatric patients with cancer as measured by a brief geriatric oncology module: a pilot experience.
    Cancer, 103(12): 2623-8. [Abstract] [Full-text]
78. Capecitabine plus docetaxel combination therapy.
    Cancer, 103(12): 2455-65. [Abstract] [Full-text]
79. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Chemotherapy, 51(2): 154-61. [Abstract] [Full-text]
80. A phase II study of docetaxel and infusional cisplatin in advanced non-small-cell lung cancer.
    Chemotherapy, 51(2): 120-5. [Abstract] [Full-text]
81. Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver.
    Chemotherapy, 51(2): 111-5. [Abstract] [Full-text]
82. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
    Cancer, 103(12): 2590-7. [Abstract] [Full-text]
83. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
    Cancer, 103(12): 2534-43. [Abstract] [Full-text]
84. Expression of caveolin-1 and its correlation with cisplatin sensitivity in oral squamous cell carcinoma.
    J Cancer Res Clin Oncol, 131(7): 445-52. [Abstract] [Full-text]
85. Modeling and simulation of cancer immunoprevention vaccine.
    Bioinformatics, 21(12): 2891-7. [Abstract] [Full-text]
86. Salvage, dose intense and high-dose chemotherapy for the treatment of poor prognosis or recurrent germ cell tumours.
    Cancer Treat Rev, 31(3): 197-209. [Abstract] [Full-text]
87. Prophylactic antibiotics for preventing early Gram-positive central venous catheter infections in oncology patients, a Cochrane systematic review.
    Cancer Treat Rev, 31(3): 186-96. [Abstract] [Full-text]
88. Understanding the enzymology of fibrinolysis and improving thrombolytic therapy.
    FEBS Lett, 579(15): 3303-9. [Abstract] [Full-text]
89. Primary care in the treatment of functional gastrointestinal symptoms in Japan: prescription preferences and impression of results.
    Aliment Pharmacol Ther, 21: 47-54. [Abstract] [Full-text]
90. The effects of 12 months of growth hormone replacement therapy on cardiac autonomic tone in adults with growth hormone deficiency.
    Clin Endocrinol (Oxf), 62(6): 706-12. [Abstract] [Full-text]
91. Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors.
    Clin Endocrinol (Oxf), 62(6): 698-705. [Abstract] [Full-text]
92. Optimum duration of prophylactic antibiotics in acute non-perforated appendicitis.
    ANZ J Surg, 75(6): 425-8. [Abstract] [Full-text]
93. Measurement of drug release from microcarriers by microdialysis.
    J Pharm Sci, 94(7): 1456-66. [Abstract] [Full-text]
94. Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma.
    Gynecol Oncol, 97(3): 893-7. [Abstract] [Full-text]
95. Phase one dose finding study of capecitabine (Xeloda), radiotherapy and cisplatin in the treatment of locally advanced squamous cervical cancer.
    Gynecol Oncol, 97(3): 790-5. [Abstract] [Full-text]
96. Identifying patients unlikely to benefit from further chemotherapy: a descriptive study of outcome at each relapse in ovarian cancer.
    Gynecol Oncol, 97(3): 862-9. [Abstract] [Full-text]
97. Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.
    Jpn J Clin Oncol, 35(5): 251-5. [Abstract] [Full-text]
98. Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up.
    Jpn J Clin Oncol, 35(5): 265-70. [Abstract] [Full-text]
99. Regional patterns of the temporal evolution of the AIDS epidemic in Brazil following the introduction of antiretroviral therapy.
    Braz J Infect Dis, 9(1): 9-19. [Abstract] [Full-text]
100. Risk factors for prediction of surgical site infections in "clean surgery".
     Am J Infect Control, 33(5): 292-8. [Abstract] [Full-text]
101. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population.
     Chest, 127(6): 2049-56. [Abstract] [Full-text]
102. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.
     Endocr Relat Cancer, 12(2): 383-92. [Abstract] [Full-text]
103. Laparoscopic adjustable gastric banding: weight loss, co-morbidities, medication usage and quality of life at one year.
     Obes Surg, 15(5): 641-7. [Abstract] [Full-text]
104. A new approach for treatment of deep skin infections by an ethosomal antibiotic preparation: an in vivo study.
     J Antimicrob Chemother, 55(6): 989-94. [Abstract] [Full-text]
105. Switch strategies in patients on effective HAART.
     J Antimicrob Chemother, 55(6): 821-3. [Abstract] [Full-text]
106. Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART.
     J Antimicrob Chemother, 55(6): 1003-7. [Abstract] [Full-text]
107. Effect of hormone replacement therapy on the production of bone-resorbing cytokines by peripheral blood cells in postmenopausal women.
     Horm Metab Res, 37(4): 226-30. [Abstract] [Full-text]
108. Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy.
     Breast Cancer Res Treat, 91(3): 217-25. [Abstract] [Full-text]
109. Aortic dissection presenting as an acute ischemic stroke for thrombolysis.
     J Neuroimaging, 15(3): 281-3. [Abstract] [Full-text]
110. Medicine labels incorporating pictograms: do they influence understanding and adherence?
     Patient Educ Couns, 58(1): 63-70. [Abstract] [Full-text]
111. Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience.
     Lung Cancer, 49: S71-4. [Abstract] [Full-text]
112. Effects of short-term inhaled nitric oxide on interleukin-8 release after single-lung transplantation in pigs.
     J Heart Lung Transplant, 24(6): 714-22. [Abstract] [Full-text]
113. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes.
     Biomaterials, 26(29): 5898-906. [Abstract] [Full-text]
114. The prevention of neonatal group B streptococcal disease: a report by a working group of the Medical Screening Society.
     J Med Screen, 12(2): 60-8. [Abstract] [Full-text]
115. A simple method for preparing an ear wick.
     J Laryngol Otol, 119(4): 306-7. [Abstract] [Full-text]
116. Acute drug prescribing to children on chronic antiepilepsy therapy and the potential for adverse drug interactions in primary care.
     Br J Clin Pharmacol, 59(6): 712-7. [Abstract] [Full-text]
117. Association of T CD4 lymphocyte levels and chronic periodontitis in HIV-infected brazilian patients undergoing highly active anti-retroviral therapy: clinical results.
     J Periodontol, 76(6): 915-22. [Abstract] [Full-text]
118. Photodynamic therapy as an adjunct to surgery for malignant pleural mesothelioma.
     Lung Cancer, 49: S65-8. [Abstract] [Full-text]
119. Photodynamic treatment with fractionated light decreases production of reactive oxygen species and cytotoxicity in vitro via regeneration of glutathione.
     Photochem Photobiol, 81(3): 609-13. [Abstract] [Full-text]
120. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.
     Br J Haematol, 129(6): 803-10. [Abstract] [Full-text]
121. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
     Br J Haematol, 129(6): 776-83. [Abstract] [Full-text]
122. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.
     Br J Haematol, 129(6): 763-70. [Abstract] [Full-text]
123. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.
     Br J Haematol, 129(6): 755-62. [Abstract] [Full-text]
124. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein.
     Mol Cancer Ther, 4(6): 956-67. [Abstract] [Full-text]
125. Undertreatment of obese women receiving breast cancer chemotherapy.
     Arch Intern Med, 165(11): 1267-73. [Abstract] [Full-text]
126. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.
     Arch Ophthalmol, 123(6): 765-73. [Abstract] [Full-text]
127. Characteristics of basal insulin requirements by age and gender in Type-1 diabetes patients using insulin pump therapy.
     Diabetes Res Clin Pract, 69(1): 14-21. [Abstract] [Full-text]
128. Socioeconomic status and use of postmenopausal hormone replacement therapy among Danish women.
     Acta Obstet Gynecol Scand, 84(7): 639-44. [Abstract] [Full-text]
129. Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.
     Br J Cancer, 92(12): 2134-9. [Abstract] [Full-text]
130. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.
     Br J Cancer, 92(12): 2129-33. [Abstract] [Full-text]
131. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
     Br J Cancer, 92(12): 2122-8. [Abstract] [Full-text]
132. Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17).
     Br J Cancer, 92(12): 2107-13. [Abstract] [Full-text]
133. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
     Clin Cancer Res, 11(12): 4533-44. [Abstract] [Full-text]
134. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia.
     Clin Cancer Res, 11(12): 4460-8. [Abstract] [Full-text]
135. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
     Clin Cancer Res, 11(12): 4444-50. [Abstract] [Full-text]
136. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
     Cancer Res, 65(12): 5439-44. [Abstract] [Full-text]
137. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.
     Cancer Res, 65(12): 5365-73. [Abstract] [Full-text]
138. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer.
     Cancer Res, 65(12): 5317-24. [Abstract] [Full-text]
139. Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor.
     Biomaterials, 26(30): 6054-67. [Abstract] [Full-text]
140. Chitosan/beta-lactoglobulin core-shell nanoparticles as nutraceutical carriers.
     Biomaterials, 26(30): 6041-53. [Abstract] [Full-text]
141. Bilateral universal nephroblastomatosis in an 8-month-old infant treated with chemotherapy.
     Pediatr Nephrol, 20(7): 1007-10. [Abstract] [Full-text]
142. Association between single nucleotide polymorphisms of estrogen receptor alpha gene and efficacy of HRT on bone mineral density in post-menopausal Japanese women.
     Hum Reprod, 20(7): 1860-6. [Abstract] [Full-text]
143. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response.
     J Infect Dis, 192(2): 296-302. [Abstract] [Full-text]
144. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals.
     J Clin Oncol, 23(18): 4192-7. [Abstract] [Full-text]
145. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
     J Clin Oncol, 23(18): 4179-91. [Abstract] [Full-text]
146. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
     J Clin Oncol, 23(18): 4172-8. [Abstract] [Full-text]
147. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study.
     J Clin Oncol, 23(18): 4137-45. [Abstract] [Full-text]
148. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
     J Clin Oncol, 23(18): 4110-6. [Abstract] [Full-text]
149. Survey of medication administration policies within schools in Sheffield.
     J Child Health Care, 9(2): 110-21. [Abstract] [Full-text]
150. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
     J Clin Oncol, 23(18): 4117-26. [Abstract] [Full-text]
151. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.
     J Clin Oncol, 23(18): 4089-99. [Abstract] [Full-text]
152. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
     J Clin Oncol, 23(18): 4079-88. [Abstract] [Full-text]
153. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
     J Clin Oncol, 23(18): 4070-8. [Abstract] [Full-text]
154. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
     J Clin Oncol, 23(18): 4031-8. [Abstract] [Full-text]
155. Medication for older people--aspects of rational therapy from the general practitioner's point of view.
     Z Gerontol Geriatr, 38(3): 190-5. [Abstract] [Full-text]
156. Development of a system to adsorb drugs onto calcium phosphate materials.
     J Mater Sci Mater Med, 16(7): 641-6. [Abstract] [Full-text]
157. Drug release from cast films of ethylene vinyl acetate (EVA) copolymer: Stability of drugs by 1H NMR and solid state 13C CP/MAS NMR.
     J Mater Sci Mater Med, 16(7): 597-605. [Abstract] [Full-text]
158. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
     Gynecol Oncol, 98(1): 141-5. [Abstract] [Full-text]
159. Patient management of long-term continuous subcutaneous insulin infusion.
     J Adv Nurs, 51(2): 112-8. [Abstract] [Full-text]
160. Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin.
     Eur J Cancer, 41(10): 1474-86. [Abstract] [Full-text]
161. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy.
     Ann Oncol, 16(7): 1133-9. [Abstract] [Full-text]
162. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
     Ann Oncol, 16(7): 1123-32. [Abstract] [Full-text]
163. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.
     Ann Oncol, 16(7): 1160-8. [Abstract] [Full-text]
164. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study.
     Ann Oncol, 16(7): 1116-22. [Abstract] [Full-text]
165. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours.
     Ann Oncol, 16(7): 1152-9. [Abstract] [Full-text]
166. Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft.
     Eur J Cancer, 41(10): 1467-73. [Abstract] [Full-text]
167. Drugs targeting the ribosome.
     Curr Opin Struct Biol, 15(3): 355-66. [Abstract] [Full-text]
168. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials.
     Eur J Cancer, 41(10): 1372-82. [Abstract] [Full-text]
169. Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: results of a multicenter retrospective Italian study.
     Gynecol Oncol, 98(1): 118-23. [Abstract] [Full-text]
170. Prophylaxis of early bacterial infections after autologous peripheral blood stem cell transplantation (PBSCT): a matched-pair study comparing oral fluoroquinolones and intravenous piperacillin-tazobactam.
     Bone Marrow Transplant, 36(1): 59-65. [Abstract] [Full-text]
171. High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT).
     Bone Marrow Transplant, 36(1): 25-31. [Abstract] [Full-text]
172. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience.
     Gynecol Oncol, 98(1): 54-8. [Abstract] [Full-text]
173. A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer.
     Ann Oncol, 16(7): 1140-6. [Abstract] [Full-text]
174. A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaïve advanced ovarian cancer.
     Gynecol Oncol, 98(1): 134-40. [Abstract] [Full-text]
175. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.
     Ann Oncol, 16(7): 1069-75. [Abstract] [Full-text]
176. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
     Ann Oncol, 16(7): 1177-84. [Abstract] [Full-text]
177. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer.
     Ann Oncol, 16(7): 1147-51. [Abstract] [Full-text]
178. Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients.
     Ann Oncol, 16(7): 1087-93. [Abstract] [Full-text]
179. Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study.
     Thromb Haemost, 93(6): 1108-16. [Abstract] [Full-text]
180. Thrombolysis increases the risk of free wall rupture in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
     J Interv Cardiol, 18(3): 167-72. [Abstract] [Full-text]
181. Safety of pulmonary administration of gemcitabine in rats.
     J Aerosol Med, 18(2): 198-206. [Abstract] [Full-text]
182. Physicochemical characterization of poly(L-lactic acid) and poly(D,L-lactide-co-glycolide) nanoparticles with polyethylenimine as gene delivery carrier.
     Int J Pharm, 298(1): 255-62. [Abstract] [Full-text]
183. Development of a controlled release formulation based on a starch matrix system.
     Int J Pharm, 298(1): 108-16. [Abstract] [Full-text]
184. Thermal analysis of the crystallization and melting behavior of lipid matrices and lipid nanoparticles containing high amounts of lecithin.
     Int J Pharm, 298(1): 242-54. [Abstract] [Full-text]
185. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.
     Blood, 106(1): 35-9. [Abstract] [Full-text]
186. An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children with type 1 diabetes.
     Diabetes Metab Res Rev, 21(4): 347-52. [Abstract] [Full-text]
187. Timing of prophylactic antibiotic administration in the uninfected laboring gravida: a randomized clinical trial.
     Am J Obstet Gynecol, 192(6): 1864-8; discussion 1868-71. [Abstract] [Full-text]
188. How to avoid paediatric medication errors: a user's guide to the literature.
     Arch Dis Child, 90(7): 698-702. [Abstract] [Full-text]
189. Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model.
     J Pharm Pharmacol, 57(6): 709-19. [Abstract] [Full-text]
190. Bridging the gap: ageing, pharmacokinetics and pharmacodynamics.
     J Pharm Pharmacol, 57(6): 671-9. [Abstract] [Full-text]
191. Chronic vulval ulceration--another immune reconstitution inflammatory syndrome?
     Int J STD AIDS, 16(6): 454-5. [Abstract] [Full-text]
192. A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK.
     J Ocul Pharmacol Ther, 21(3): 236-41. [Abstract] [Full-text]
193. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
     N Engl J Med, 352(25): 2589-97. [Abstract] [Full-text]
194. Role of adjuvant chemotherapy in the treatment of non-small-cell lung cancer.
     Am J Health Syst Pharm, 62(13): 1365-9. [Abstract] [Full-text]
195. Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial.
     J Thromb Thrombolysis, 19(1): 33-9. [Abstract] [Full-text]
196. Evaluation of coronary artery patency using cardiac markers.
     J Thromb Thrombolysis, 19(1): 21-4. [Abstract] [Full-text]
197. Evaluation of recombinant human bone morphogenetic protein-2 on the repair of alveolar ridge defects in baboons.
     J Periodontol, 76(2): 210-20. [Abstract] [Full-text]
198. Use of the transtheoretical model in the medication use process.
     Ann Pharmacother, 39(7): 1325-30. [Abstract] [Full-text]
199. Effect of hepatitis C virus coinfection on humoral immune alterations in naïve HIV-infected adults on HAART: a three year follow-up study.
     J Clin Immunol, 25(3): 296-302. [Abstract] [Full-text]
200. In vitro and in vivo bactericidal activities of vancomycin dispersed in porous biodegradable poly(epsilon-caprolactone) microparticles.
     Antimicrob Agents Chemother, 49(7): 3025-7. [Abstract] [Full-text]
201. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women.
     Am J Cardiol, 96(1): 148-53. [Abstract] [Full-text]
202. Payment mechanisms and prescriptions in four Thai hospitals.
     Health Policy, 73(2): 160-71. [Abstract] [Full-text]
203. Characteristics of complement activation in mice bearing Lewis lung carcinomas treated by photodynamic therapy.
     Cancer Lett, 225(2): 215-23. [Abstract] [Full-text]
204. Minor inflammation after surgical evacuation compared with fibrinolytic therapy of experimental intracerebral hemorrhages.
     Neurol Res, 27(5): 493-8. [Abstract] [Full-text]
205. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium.
     Eur J Pharm Sci, 25(4): 455-65. [Abstract] [Full-text]
206. Comparative scale-up of three methods for producing ibuprofen-loaded nanoparticles.
     Eur J Pharm Sci, 25(4): 357-67. [Abstract] [Full-text]
207. Improving local control with breast-conserving therapy: a 27-year single-institution experience.
     Cancer, 104(1): 20-9. [Abstract] [Full-text]
208. A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia.
     Cancer, 104(1): 143-8. [Abstract] [Full-text]
209. Salt formation in solid dispersions consisting of polyacrylic acid as a carrier and three basic model compounds resulting in very high glass transition temperatures and constant dissolution properties upon storage.
     Eur J Pharm Sci, 25(4): 387-93. [Abstract] [Full-text]
210. Microencapsulated chitosan nanoparticles for lung protein delivery.
     Eur J Pharm Sci, 25(4): 427-37. [Abstract] [Full-text]
211. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo.
     Eur J Pharm Sci, 25(4): 445-53. [Abstract] [Full-text]
212. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan.
     Am J Respir Crit Care Med, 172(1): 123-7. [Abstract] [Full-text]
213. Hyperosmolar hyperglycemic state.
     Emerg Med Clin North Am, 23(3): 629-48, vii. [Abstract] [Full-text]
214. Thrombolytic therapy use for acute myocardial infarction and outcome in Qatar.
     Int J Cardiol, 102(2): 249-54. [Abstract] [Full-text]
215. Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial.
     Br J Haematol, 130(1): 67-75. [Abstract] [Full-text]
216. Can chest ultrasonography assess pleurodesis after VATS for spontaneous pneumothorax?
     Eur J Cardiothorac Surg, 28(1): 47-9. [Abstract] [Full-text]
217. Incidence of contrast nephropathy in patients receiving comprehensive intravenous and oral hydration.
     Swiss Med Wkly, 135(19): 286-90. [Abstract] [Full-text]
218. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
     Breast Cancer Res Treat, 92(2): 151-6. [Abstract] [Full-text]
219. An evaluation of antimicrobial prophylaxis in paediatric surgery and its financial implication.
     J Clin Pharm Ther, 30(4): 371-81. [Abstract] [Full-text]
220. Declining gastrointestinal opportunistic infections in HIV-infected persons: a triumph of science and a challenge for our HAARTs and minds.
     Am J Gastroenterol, 100(7): 1455-8. [Abstract] [Full-text]
221. Decline in esophageal candidiasis and use of antimycotics in European patients with HIV.
     Am J Gastroenterol, 100(7): 1446-54. [Abstract] [Full-text]
222. Photodynamic effects of a novel pterin derivative on a pancreatic cancer cell line.
     Biochem Biophys Res Commun, 333(3): 763-7. [Abstract] [Full-text]
223. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer.
     Jpn J Clin Oncol, 35(6): 316-23. [Abstract] [Full-text]
224. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
     Jpn J Clin Oncol, 35(6): 332-7. [Abstract] [Full-text]
225. Antibiotic prescription in primary health care: clinical and economic perspectives (Catalonia, Spain).
     Eur J Public Health, 15(3): 276-81. [Abstract] [Full-text]
226. Controlled release of tethered molecules via engineered hydrogel degradation: model development and validation.
     J Biomed Mater Res A, 74(1): 104-16. [Abstract] [Full-text]
227. A long-term survival case of small cell lung cancer in an HIV-infected patient.
     Jpn J Clin Oncol, 35(6): 349-52. [Abstract] [Full-text]
228. Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study.
     Eur Heart J, 26(14): 1362-8. [Abstract] [Full-text]
229. Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy.
     Eur Heart J, 26(14): 1358-61. [Abstract] [Full-text]
230. The role of adjuvant chemotherapy in children and adolescents with surgically resected, high-risk adult-type soft tissue sarcomas.
     Pediatr Blood Cancer, 45(2): 128-34. [Abstract] [Full-text]
231. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study.
     Support Care Cancer, 13(7): 554-8. [Abstract] [Full-text]
232. Influence of tumours on normal cells and optimal chemotherapy regimens: the case of several drugs and toxicity constraints.
     Math Med Biol, 22(2): 143-62. [Abstract] [Full-text]
233. Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation.
     Support Care Cancer, 13(7): 522-8. [Abstract] [Full-text]
234. Early bacteremia in pediatric hematopoietic stem cell transplant patients on oral antibiotic prophylaxis.
     Pediatr Blood Cancer, 45(2): 162-9. [Abstract] [Full-text]
235. Veno-occlusive disease of the liver associated with chronic myelomonocytic leukemia treated with vincristine and standard doses of cytarabine.
     Am J Hematol, 79(3): 216-9. [Abstract] [Full-text]
236. Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders.
     Am J Hematol, 79(3): 211-5. [Abstract] [Full-text]
237. Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment.
     Stat Med, 24(14): 2151-70. [Abstract] [Full-text]
238. Potential for drug interactions in hospitalized cancer patients.
     Cancer Chemother Pharmacol, 56(3): 286-90. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.